Tonix Pharmaceuticals : Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress - Form 8-K
Tonix Pharmaceuticals Holding Corp. , a clinical-stage biopharmaceutical company, today announced data from three oral presentations at the 2022 American Transplant Congress by faculty at the Center... | June 9, 2022
Source: marketscreener.com